Hot
重组抗人CD3e单抗(UCHT1) | Syd Labs PA007197
体内实验级重组抗人CD3e单克隆抗体（克隆：UCHT1，Syd Labs货号PA007197），小鼠IgG1 Kappa（In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: UCHT1)，Mouse IgG1 Kappa）。适用于体外和体内研究，纯度>95%。可配套小鼠IgG1同型对照抗体使用，样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007197 |
|---|---|
| 产品名称 | 重组抗人CD3e单抗(UCHT1) | Syd Labs PA007197 |
| 英文名 | In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: UCHT1)，Mouse IgG1 Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 分化簇3，CD3D，CD3E，CD3G（cluster of differentiation 3, CD3D, CD3E, CD3G） |
| 概述 | Syd Labs提供重组小鼠 IgG1同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定（Recombinant Mouse IgG1 isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator）。 |
| 克隆号 | UCHT1 |
| 同种型 | Mouse IgG1 kappa |
| 免疫源 | 抗人CD3e单克隆抗体(克隆号: UCHT1)是在哺乳动物细胞中产生的 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质。提供特级体内实验级重组抗人CD3e单克隆抗体(克隆号UCHT1)，小鼠IgG1 Kappa（In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: UCHT1)，Mouse IgG1 Kappa)。 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD3e单克隆抗体(克隆号UCHT1)，小鼠IgG1 Kappa（In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: UCHT1)，Mouse IgG1 Kappa)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007197 Syd Labs提供重组小鼠 IgG1同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定（Recombinant Mouse IgG1 isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator）。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人CD3蛋白影响的生物学途径的测定。 |
文献
PA007197: Syd Labs抗人CD3e单克隆抗体(克隆号UCHT1) ，体内实验级重组，小鼠IgG1 Kappa（In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: UCHT1)，Mouse IgG1 Kappa）
小鼠抗人CD3单克隆抗体（克隆号：UCHT1，小鼠IgG1 kappa）可与由人CD3E基因编码的人CD3ε（epsilon）链蛋白（T3或分化群3）发生反应，该蛋白是T细胞受体（TCR）复合物的关键信号转导组件。CD3在所有成熟的人T淋巴细胞上均呈均匀表达，并在适应性免疫应答中发挥着不可或缺的作用。研究表明，在高级肿瘤免疫学分析和结构生物学模型中，可通过抗人CD3抗体处理和受体-配体竞争性分析来评估并阻断特定的细胞信号通路。UCHT1功能性抗体能够有效结合人CD3复合物的构象外显表位，是专业临床前研究中的行业标准分子工具。
我们的重组抗人CD3 UCHT1抗体经过精心工程化，保留了来源于原始杂交瘤的100%精确可变区氨基酸序列。该体内实验级UCHT1抗体采用先进的哺乳动物细胞表达，具备经验证的高结合亲和力和优异的结构稳定性，提供出色的批间一致性。这款抗人CD3克隆号UCHT1小鼠IgG1试剂以无载体无抑菌剂的专用缓冲液提供，为低内毒素抗人CD3 UCHT1配方（<1 EU/mg，无叠氮化物，不含稳定剂），可消除非特异性细胞激活或背景细胞毒性。这使其成为高通量抗CD3 UCHT1中和实验、生物学通路追踪、药代动力学（PK）评估以及高级生物分析抗药物抗体（ADA）筛选级联反应的终极标杆标准。
抗人CD3e单抗(UCHT1)部分引用文献:
1. In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 limits tumor growth in a humanized mouse model
Wei, J., et al. Mol Ther Oncolytics. 2022 Sep. doi: 10.1016/j.omto.2022.09.006
“This study evaluates a DNA-launched bispecific T cell engager (BiTE) targeting IL-13Rα2 in a humanized NSG mouse model engrafted with human PBMCs. Flow cytometry analysis utilized anti-human CD45 (HI30), anti-human CD3 (UCHT1), anti-human CD4 (OKT4)… The IL-13Rα2 BiTE significantly reduced tumor growth compared to controls.”
Wei, J., et al. Mol Ther Oncolytics. 2022 Sep. doi: 10.1016/j.omto.2022.09.006
“This study evaluates a DNA-launched bispecific T cell engager (BiTE) targeting IL-13Rα2 in a humanized NSG mouse model engrafted with human PBMCs. Flow cytometry analysis utilized anti-human CD45 (HI30), anti-human CD3 (UCHT1), anti-human CD4 (OKT4)… The IL-13Rα2 BiTE significantly reduced tumor growth compared to controls.”
2. SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution
Argüello, R. J., et al. Cell Metab. 2020 Dec. doi: 10.1016/j.cmet.2020.11.007
“This study introduces SCENITH, a flow cytometry-based method to profile energy metabolism at single-cell resolution. Immune cell phenotyping was performed using antibodies including anti-CD45 (HI30), anti-CD3 (UCHT1), anti-CD4 (RPA-T4)… SCENITH measures protein synthesis rates as a proxy for cellular energy metabolism, validated in human immune cells.”
Argüello, R. J., et al. Cell Metab. 2020 Dec. doi: 10.1016/j.cmet.2020.11.007
“This study introduces SCENITH, a flow cytometry-based method to profile energy metabolism at single-cell resolution. Immune cell phenotyping was performed using antibodies including anti-CD45 (HI30), anti-CD3 (UCHT1), anti-CD4 (RPA-T4)… SCENITH measures protein synthesis rates as a proxy for cellular energy metabolism, validated in human immune cells.”
3. An IgG-based bispecific antibody for improved dual targeting in vivo
Kellner, S., et al. EMBO Mol Med. 2020. doi: 10.15252/emmm.201911902
“This study investigates an IgG-based bispecific antibody in NSG mice engrafted with human PBMCs and tumor cells. T cells were stained with anti-CD3 (UCHT1) and anti-CD8 (SK1) antibodies for flow cytometry analysis… peripheral blood analyzed for T cell activation and cytokine release post-treatment.”
Kellner, S., et al. EMBO Mol Med. 2020. doi: 10.15252/emmm.201911902
“This study investigates an IgG-based bispecific antibody in NSG mice engrafted with human PBMCs and tumor cells. T cells were stained with anti-CD3 (UCHT1) and anti-CD8 (SK1) antibodies for flow cytometry analysis… peripheral blood analyzed for T cell activation and cytokine release post-treatment.”
4. In vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and in vivo Toxicology in Non-Human Primates
Wang, C., et al. Cancer Immunol Res. 2014. doi: 10.1158/2326-6066.CIR-14-0040
“This study characterizes the anti-PD-1 antibody nivolumab in vitro and evaluates its toxicology in cynomolgus monkeys. Flow cytometry was performed using anti-CD3 (UCHT1), anti-CD4 (L200), and anti-CD8 (RPA-T8) antibodies… Nivolumab binding to PD-1 was confirmed on activated T cells.”
Wang, C., et al. Cancer Immunol Res. 2014. doi: 10.1158/2326-6066.CIR-14-0040
“This study characterizes the anti-PD-1 antibody nivolumab in vitro and evaluates its toxicology in cynomolgus monkeys. Flow cytometry was performed using anti-CD3 (UCHT1), anti-CD4 (L200), and anti-CD8 (RPA-T8) antibodies… Nivolumab binding to PD-1 was confirmed on activated T cells.”
5. Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics
Staroverov, R. M. T., et al. Mol Cancer Ther. 2009. doi: 10.1158/1535-7163.MCT-08-1160
“This study evaluates light-activatable UCHT1-folate conjugates in nude mice bearing ovarian cancer xenografts. Flow cytometry confirmed T cell binding using anti-CD3 (UCHT1) antibody… The conjugate significantly reduced tumor growth compared to non-irradiated controls.”
Staroverov, R. M. T., et al. Mol Cancer Ther. 2009. doi: 10.1158/1535-7163.MCT-08-1160
“This study evaluates light-activatable UCHT1-folate conjugates in nude mice bearing ovarian cancer xenografts. Flow cytometry confirmed T cell binding using anti-CD3 (UCHT1) antibody… The conjugate significantly reduced tumor growth compared to non-irradiated controls.”